MEAI
MEAI (5-methoxy-2-aminoindane or 5-MeO-AI or Chaperon) is a recreational drug and binge-drinking prevention drug, first chemically described in 1980,[1][2] and first pharmacologically described in a peer reviewed paper in 2017 by David Nutt et al.,[3] followed by another in February 2018 which detailed pharmacokinetics, pharmacodynamics and metabolism of MEAI.[4] In 2018, a company in the United States began offering an MEAI-based drink called "Pace".[5]
![]() | |
| Clinical data | |
|---|---|
| Other names | 5-MeO-AI; 2,3-Dihydro-5-methoxy-1H-Inden-2-amine |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H13NO |
| Molar mass | 163.220 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
MEAI was an early candidate of alcohol replacement drugs that came to market during a late 2010s movement to replace alcohol with less-toxic alternatives spearheaded by British psychopharmacologist David Nutt. Though MEAI was made commercially available online in the United States as "Pace", Nutt's commercial efforts moved away from direct marketing of MEAI in favor of Alcarelle.[6]
References
- Sainsbury, P.D.; Kicman, A.T.; Archer, R.P.; King, L.A.; Braithwaite, R.A. (2011). "Aminoindanes-the next wave of 'legal highs'?". Drug Testing and Analysis. 3 (7–8): 479–482. doi:10.1002/dta.318. PMID 21748859.
- Cannon, Joseph G.; Perez, Julio A.; Pease, Jonathan P.; Long, John Paul; Flynn, Jan R.; Rusterholz, David B.; Dryer, Stuart E. (1980). "Comparison of biological effects of N-alkylated congeners of .beta.-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene". Journal of Medicinal Chemistry. 23 (7): 745–749. doi:10.1021/jm00181a009.
- Shimshoni, Jakob A.; Winkler, Ilan; Edery, Nir; Golan, Ezekiel; Van Wettum, René; Nutt, David (2017). "Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development". Toxicology and Applied Pharmacology. 319: 59–68. doi:10.1016/j.taap.2017.01.018. ISSN 1096-0333. PMID 28167221.
- Shimshoni, Jakob A.; Sobol, Eyal; Golan, Ezekiel; Ben Ari, Yulius; Gal, Orit (March 2018). "Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAI): A new binge-mitigating agent". Toxicology and Applied Pharmacology. 343: 29–39. doi:10.1016/j.taap.2018.02.009.
- Pace, Drink. "Pace by DACOA". Pace. DACOA. Retrieved 12 August 2018.
- "Alcarelle".
